| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2766336 | Medicina Paliativa | 2015 | 5 Pages |
Abstract
Despite adequate control of chronic cancer pain with major opioids, some patients experience transitory and intense exacerbations. These exacerbations, known as breakthrough pain, are characterized by rapid onset, short duration and strong intensity. Episodes of breakthrough pain require specific treatment with analgesics tailored to relieve this type of pain. Notable among these analgesics is a transmucosal nasal fentanyl formulation in a pectin-based gel (PecFent®), whose clinical development is summarized in this article.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Luis Cabezón Gutiérrez, Parham Khosravi Shahi,